The overall safety profile was similar to that demonstrated in previous studies ; tapentadol ER was associated with a lower incidence of gastrointestinal treatment-emergent adverse events than morphine SR -LSB- @ % ( @/@ ) vs. @ % ( @/@ ) -RSB- , including constipation -LSB- @ % ( @/@ ) vs. @ % ( @/@ ) -RSB- and vomiting -LSB- @ % ( @/@ ) vs. @ % ( @/@ ) -RSB- .